Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cephalon
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
ELIGIBILITY:
Documented B-cell Non-Hodgkin's Lymphoma
Small lymphocytic lymphoma (ALC \< 5,000 cells/mm3)
Marginal zone B-cell lymphoma (nodal, extranodal, or splenic types)
Lymphoplasmacytic lymphoma
Follicular center lymphoma, follicular
Disease documented to be refractory to a full-course of the most recent rituximab therapy (single agent or combination)
At least 1 prior chemotherapy regimen and maximum of 3 prior chemotherapy regimens
Bidimensionally measurable disease (by CT scan) with at least one lesion measuring ≥ 2.0 cm in a single dimension
You may not be if
Patients who receive rituximab only as part of treatment with ibritumomab tiuxetan (Zevalin®) will not be eligible
History of prior high dose chemotherapy with allogeneic stem cell support (history of autologous stem cell support is permissible)
Clareo Health | Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab
